E-110 | Outcomes of PCI among patients on Finerenone: A Propensity Matched Retrospective Cohort Study
Finerenone is known to improve cardiorenal outcomes among those with type 2 diabetes and stage 2 to 4 CKD as well as in patients with mildly reduced and preserved EF. Finerenone inhibits the effects of mineralocorticoids like aldosterone and cortisol when the mineralocorticoid receptor is overactivated, possibly reducing inflammation and fibrosis in the heart and kidney. Its impact on outcomes following percutaneous coronary intervention (PCI) remains unclear. This study compares PCI outcomes in patients on Finerenone versus those not on it.
Authors
- Kintur Sanghvi (ORCID: https://orcid.org/0000-0003-2981-7885)
- Rakendu Jayasree Rajendran
- Hitesh Bhatia (ORCID: https://orcid.org/0000-0002-0099-061X)
- Abdallah Hussein
Institutions
- SUNY Upstate Medical University (US)
- Our Lady of Lourdes Medical Center (US)
- Guthrie Robert Packer Hospital (US)
- Lourdes Hospital (US)
Publication Details
- Journal
- Journal of the Society for Cardiovascular Angiography & Interventions
- Published
- 2025-05-01
- DOI
- https://doi.org/10.1016/j.jscai.2025.103371
- Primary Topic
- Hormonal Regulation and Hypertension
- Type
- article
- Field-Weighted Citation Impact
- 0.00